Diatherix Revenue and Competitors

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Diatherix's estimated annual revenue is currently $26M per year.(i)
  • Diatherix's estimated revenue per employee is $155,000

Employee Data

  • Diatherix has 168 Employees.(i)
  • Diatherix grew their employee count by -13% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$11.2M729%N/AN/A
#2
$0.9M6200%N/AN/A
#3
$3.7M2414%N/AN/A
#4
$2.3M15-25%N/AN/A
#5
$18M116-1%N/AN/A
#6
$0.9M6-33%N/AN/A
#7
$3.4M220%N/AN/A
#8
$1.7M1122%N/AN/A
#9
$4.2M27-7%N/AN/A
#10
$26M168-13%N/AN/A
Add Company

A unique laboratory providing accurate and actionable results in one day for infectious diseases and antibiotic resistance genes utilizing innovative molecular technologies, including proprietary TEM-PCRᅢᄁ¬ダᅡᄁ. Diatherix Eurofins distinctions: - Delivers one-day results - Identifies bacteria regardless of recent antibiotic use - Offers simplicity of single-sample collection - Identifies difficult-to-culture pathogens - Yields a high level of sensitivity and specificity

keywords:N/A

N/A

Total Funding

168

Number of Employees

$26M

Revenue (est)

-13%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Diatherix News

2022-04-20 - Hospital-Acquired Disease Testing Market Size, Outlook And ...

Diatherix Laboratories, Gen-Probe, Qiagen, F. Hoffmann-La Roche, Cepheid, Life Technologies Corporation, Meridian Biosciences,...

2022-04-06 - Methicillin-resistant Staphylococcus Aureus (MRSA) Testing ...

... F.Hoffmann-La Roche, Hain Lifescience, Biomerieux, 3M, Bio-Rad Laboratories, Abacus Diagnostica, Abbott, Puritan Medical, Diatherix.

2022-03-22 - Madison Core Laboratories Appoints New Chief Scientific Officer

Previously he served as the Chief Scientific Officer and Clinical Laboratory Director for Diatherix-Eurofins, in Huntsville, Alabama.

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$56.9M1681%N/A
#2
$56.9M16814%N/A
#3
$61M1688%N/A
#4
$56.9M168-6%N/A
#5
$46.1M1719%N/A